

#### Contents lists available at ScienceDirect

## **Fitoterapia**

journal homepage: www.elsevier.com/locate/fitote



# Cytotoxic and anti-inflammatory active plicamine alkaloids from *Zephyranthes grandiflora*



Hong-Yong Wang<sup>a</sup>, Sheng-Ming Qu<sup>b</sup>, Ying Wang<sup>c</sup>, Hai-Tao Wang<sup>d,\*</sup>

- <sup>a</sup> Department of Radiotherapy, Second Hospital of Jilin University, Changchun 130041, China
- <sup>b</sup> Department of Dermatology, Second Hospital of Jilin University, Changchun 130041, China
- <sup>c</sup> Department of Gastroenterology, First Hospital of Jilin University, Changchun 130021, China
- <sup>d</sup> Department of E.N.T., Second Hospital of Jilin University, Changchun 130041, China

#### ARTICLE INFO

#### Keywords: Zephyranthes grandiflora Amaryllidaceae Alkaloids Cytotoxic Anti-inflammatory activity

#### ABSTRACT

Phytochemical investigation on the 95% EtOH extract of the whole plants of *Zephyranthes grandiflora* resulted in the isolation of six new 4a-*epi*-plicamine-type alkaloids, zephygranditines A-F (1–6), including three novel 11,12-*seco*-plicamine-type alkaloids. The structures of the isolated compounds were established based on 1D and 2D ( $^{1}H^{-1}H$  COSY, HMQC, and HMBC) NMR spectroscopy, in addition to high resolution mass spectrometry. The isolated alkaloids were tested *in vitro* for cytotoxic potential against seven malignant melanoma cell lines and inhibitory activity for nitric oxide (NO) production and Cox-1/Cox-2. As a result, alkaloids 1–3 exhibited some cytotoxic activity against all the tested tumor cell lines with IC<sub>50</sub> values < 20  $\mu$ M and 1 and 2 displayed anti-inflammatory activity in both assay of inhibitory activity for nitric oxide production and Cox-1/Cox-2.

#### 1. Introduction

The genus Zephyranthes, belonging to the family of Amaryllidaceae, consists of 60 species which distribute mainly in the warm-temperate regions of Western Hemisphere [1,2]. Plants of this family are well known for their ornamental value and medicinal properties [3]. Traditionally, Z. candida has been used in Africa for anti-diabetes and Z. parulla appears in the history of Peru for treating tumors, Z. rosea and Z. flava are used for variety of therapeutic purposes in India [4-6]. To date, > 600 Amaryllidaceae alkaloids representing 22 skeletal types have been reported [7], and some of them exhibit a wide variety of biological activities including acetylcholinesterase (AChE) inhibitory, analgesic, antibacterial, antifungal, antimalarial, antitumor, antiviral, and cytotoxic activities [8-11]. Thus, the Amaryllidaceae alkaloids are an important resource for new drug discovery [12]. Zephyranthes grandiflora mainly distributes in the temperate zone of Western Hemisphere and is used as an ornamental and medicinal plant in China [13]. Chemical investigations have discovered the presence of Amaryllidaceae alkaloids [3,13,14]. To find more structurally interesting substances of the genus Zephyranthes, a phytochemical investigation on the 95% ethanol extract of the whole plants of Z. grandiflora afforded six new alkaloids, including three 4a-epi-plicamine-type alkaloids, zephygranditines A-C (1-3), and three 11,12-seco-plicamine-type alkaloids, zephygranditines D-F (4-6) (Fig. 1). The novel plicamine-type alkaloids with *N*-deformyl-11,12-*seco*-5,6-dihydroplicane and 11,12-*seco*-5,6-dihydroplicane skeleton, which were obtained only from *Z. candida*, were formed by the cleavage between C-11 and C-12 of 4a-*epi*-plicamine-type alkaloids. This paper described the isolation and structure elucidation of the new compounds, as well as their *in vitro* cytotoxic and anti–inflammatory activities.

#### 2. Experimental part

#### 2.1. General

Optical rotations were determined with a JASCO P2000 digital polarimeter. Ultraviolet (UV) and infrared (IR) spectra were obtained on JASCO V-650 and JASCO FT/IR-4100 spectrophotometers, respectively. ECD spectra were recorded using JASCO *J*-810 instruments (JASCO Corporation, Tokyo, Japan). The NMR spectra were recorded on a Varian Unity INOVA 500 FT-NMR spectrometer (Varian Medical Systems, Salt Lake City, UT, USA; 500 MHz for  $^1\mathrm{H}$ ; 125 MHz for  $^{13}\mathrm{C}$ , respectively). Chemical shifts were reported using residual CDCl $_3$  ( $\delta_\mathrm{H}$ 7.26 and  $\delta_\mathrm{C}$ 77.0 ppm) and CD $_3$ OD ( $\delta_\mathrm{H}$ 3.30 and  $\delta_\mathrm{C}$ 49.0 ppm) as internal standard. High resolution ESI-MS spectra were obtained on a LTQ Orbitrap XL (Thermo Fisher Scientific, Waltham, MA, USA) spectrometer. Silica gel 60 (Merck, Darmstadt, Germany, 230–400 mesh), LiChroprep RP-18 (Merck, 40–63 µm), and Sephadex LH-20 (Amersham

E-mail address: wanghaitao1912@sina.com (H.-T. Wang).

<sup>\*</sup> Corresponding author.

H.-Y. Wang et al. Fitoterapia 130 (2018) 163–168

Fig. 1. Structures of compounds 1-6.

Pharmacia Biotech., Roosendaal, The Netherlands) were used for column chromatography (CC). Precoated silica gel plates (Merck, Kieselgel 60 F254, 0.25 mm) and precoated RP-18  $F_{254s}$  plates (Merck) were used for analytical thin-layer chromatography analyses. HPLC separation was performed on an instrument consisting of a Waters 600 controller, a Waters 600 pump, and a Waters 2487 dual  $\lambda$  absorbance detector, with a Prevail (250  $\times$  10 mm i.d.) preparative column packed with  $C_{18}$  (5  $\mu m$ ).

#### 2.2. Plant material

The whole plants of *Z. grandiflora* were collected in June 2017 at the suburb of Changchun, Jilin Province of China. A specimen (No. 20170601ZF) was identified by one of the authors (H.T. Wang) and deposited at the Natural Product Laboratory of Medical School, Jilin University, China.

#### 2.3. Extraction and isolation

The air-dried whole plants of Z. grandiflora (10.0 kg) were cut into small pieces and were extracted with 95% EtOH (25 L  $\times$  3) at room temperature for 24 h each time. After removal of EtOH under reduced pressure at 55 °C, the aqueous brownish syrup (1 L) was suspended in  $H_2O$  (4L) and then partitioned with chloroform (5L  $\times$  3) to afford chloroform soluble fraction (55.3 g). The chloroform soluble fraction was further fractionated through a silica gel column (200-300 mesh, 10 × 80 cm, 500 g) using increasing a proportion of methanol in chloroform (100:1, 50:1, 30:1, 15:1, 10:1, 7:1, 5:1, 3:1, 1:1, v/v, each 2.5 L) as the eluent to give 6 fractions according to TLC analysis. Fraction 3 (methanol-chloroform 15:1, 3.6 g) was applied to an ODS MPLC column (8 cm  $\times$  40 cm, 150 g) and eluted with MeOH-H<sub>2</sub>O (20:80, 30:70, 40:60, each 500 mL) to yield 4 subfractions (Fr. 3-1 and Fr. 3-4). Subfraction 3-2 (MeOH-H<sub>2</sub>O, 520 mg) was purified by preparative RP-HPLC (ODS column,  $250 \times 20 \, \text{mm}$ ) using MeOH-H<sub>2</sub>O (20:80) as mobile phase to obtain 5 (71 mg, 240 nm, retention time: 13.3 min). Subfraction 3-3 (MeOH-H<sub>2</sub>O, 350 mg) was purified by preparative RP-HPLC (ODS column, 250 × 20 mm) eluting with MeOH/  $H_2O$  (22:78) to get **6** (57 mg, 240 nm, retention time: 14.7 min). Subfraction 3-4 (MeOH-H<sub>2</sub>O 40:60, 210 mg) was purified by preparative RP-HPLC (ODS column, 240 nm,  $250 \times 20$  mm) eluting with MeOH/H<sub>2</sub>O (22% of MeOH-H<sub>2</sub>O) to get 3 (55 mg, 240 nm, retention time: 14.6 min). Fraction 4 (methanol-chloroform 7:1, 2.9 g) was applied to an ODS MPLC column (8 cm × 40 cm, 150 g) and eluted with MeOH-H<sub>2</sub>O (20:80, 30:70, 40:60, each 500 mL) to yield 3 subfractions (Fr. 4-1 and Fr. 4-3). Subfraction 4-1 (MeOH-H<sub>2</sub>O 20:80, 226 mg) was repeatedly chromatographed on silica gel (150 g, 60 × 2.8 cm, chloroform-methanol,  $20:1 \rightarrow 10:1$ , each 500 mL) and then purified by preparative RP-HPLC (ODS column,  $250 \times 20 \,\mathrm{mm}$ ) using MeOH-H<sub>2</sub>O (25:75) as mobile phase to obtain 2 (61 mg, 240 nm, retention time: 13.5 min). Subfraction 4–2 (MeOH-H<sub>2</sub>O, 50:50, 265 mg)

chromatographed by a Sephadex LH-20 column (2  $\times$  200 cm, 150 g) eluted with MeOH-H<sub>2</sub>O (50% of MeOH-H<sub>2</sub>O), and purifed on preparative RP-HPLC (ODS column, 250  $\times$  20 mm) using MeOH-H<sub>2</sub>O (30:70) as mobile phase to yield 4 (78 mg, retention time: 15.0 min). Subfraction 4–3 was purified by preparative RP-HPLC (ODS column, 250  $\times$  20 mm) eluting with MeOH/H<sub>2</sub>O (20:80) to get 1 (77 mg, 240 nm, retention time: 15.5 min).

#### 2.3.1. Zephygranditine A (1)

Colorless oil; [ $\alpha$ ] +77.2 (c 0.10, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\epsilon$ ): 208 (4.18), 226 (4.35), 235 (4.18), 302 (3.66) nm; ECD (MeOH) 206 ( $\Delta\epsilon$  + 12.91), 226 ( $\Delta\epsilon$  + 29.39), 255 ( $\Delta\epsilon$  + 1.95), 263 ( $\Delta\epsilon$  + 2.76) nm; IR (KBr)  $\nu_{max}$  2954, 2931, 1708, 1648, 1473, 1266, 1084, 1035, 933 cm $^{-1}$ ;  $^{1}$ H and  $^{13}$ C NMR: Tables 1 and 2; HR-ESI-MS m/z: 413.2079 ( $C_{23}H_{29}N_{2}O_{5}$  [M + H] $^{+}$ , calc. 413.2076).

#### 2.3.2. Zephygranditine B (2)

Colorless oil; [ $\alpha$ ] +70.3 (c 0.10, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\varepsilon$ ): 208 (4.70), 227 (4.33), 237 (3.89), 292 (3.78), 303 (3.68) nm; ECD (MeOH) 207 ( $\Delta\varepsilon$  +12.27), 225 ( $\Delta\varepsilon$  +27.67), 257 ( $\Delta\varepsilon$  +1.90), 264 ( $\Delta\varepsilon$  +2.74) nm; IR (KBr)  $\nu_{max}$  2952, 2929, 2892, 1707, 1650, 1501, 1483, 1387, 1267, 1085, 1037, 932 cm  $^{-1}$ ;  $^{1}$ H and  $^{13}$ C NMR: Tables 1 and 2; HR-ESI-MS m/z: 447.1924 ( $C_{26}$ H<sub>27</sub>N<sub>2</sub>O<sub>5</sub> [M + H]  $^{+}$ , calc. 447.1920).

#### 2.3.3. Zephygranditine C (3)

Colorless oil; [ $\alpha$ ] + 36.1 (c 0.10, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\epsilon$ ): 208 (4.24), 223 (3.94), 242 (3.70), 292 (3.56) nm; ECD (MeOH) 207 ( $\Delta\epsilon$  +17.72), 224 ( $\Delta\epsilon$  +9.72) nm; IR (KBr)  $\nu$ max 2951, 2929, 2868, 1762, 1614, 1502, 1484, 1388, 1244, 1097, 934 cm $^{-1}$ ;  $^{1}$ H and  $^{13}$ C NMR: Tables 1 and 2; HR-ESI-MS m/z: 401.2079 ( $C_{22}H_{29}N_{2}O_{5}$  [M + H] $^{+}$ , calc. 401.2076).

#### 2.3.4. Zephygranditine D (4)

Colorless oil; [ $\alpha$ ] +19.0 (c 0.10, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\varepsilon$ ): 208 (4.30), 225 (3.79), 237 (3.87), 291 (3.57) nm; ECD (MeOH) 205 ( $\Delta\varepsilon$  +18.97), 237 ( $\Delta\varepsilon$  +4.17), 288 ( $\Delta\varepsilon$  +1.73) nm; IR (KBr)  $\nu$ max 3333, 2953, 2930, 1688, 1643, 1483, 1425, 1237, 1089, 1037, 935 cm $^{-1}$ ;  $^{1}$ H and  $^{13}$ C NMR: Tables 1 and 2; HR-ESI-MS m/z: 421.2133 ( $C_{25}H_{29}N_{2}O_{4}$  [M + H] $^{+}$ , calc. 421.2127).

#### 2.3.5. Zephygranditine E (5)

Colorless oil;  $[\alpha]$  +104.2 (c 0.10, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\epsilon$ ): 208 (4.36), 226 (4.28), 242 (3.75), 291 (3.60) nm; ECD (MeOH) 205 ( $\Delta\epsilon$  +19.27), 234 ( $\Delta\epsilon$  +5.51), 287 ( $\Delta\epsilon$  +2.47) nm; IR (KBr)  $\nu$ max 3332, 2952, 2933, 2871, 2820, 2764, 1684, 1513, 1482, 1239, 1081, 1036, 931 cm $^{-1}$ ;  $^{1}$ H and  $^{13}$ C NMR: Tables 1 and 2; HR-ESI-MS m/z: 451.2228 ( $C_{26}H_{31}N_{2}O_{5}$  [M + H] $^{+}$ , calc. 451.2233).

#### 2.3.6. Zephygranditine F (6)

Colorless oil; [ $\alpha$ ] +77.2 (c 0.10, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\epsilon$ ):

### Download English Version:

# https://daneshyari.com/en/article/9954902

Download Persian Version:

https://daneshyari.com/article/9954902

<u>Daneshyari.com</u>